AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID-19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary) ; Ritonavir
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 27 Feb 2024 Status changed from active, no longer recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 26 Feb 2024 to 15 Feb 2024.
- 12 Sep 2023 Planned primary completion date changed from 8 Oct 2023 to 27 Sep 2023.